Identification

Name
Warfarin
Accession Number
DB00682  (APRD00341)
Type
Small Molecule
Groups
Approved
Description

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Structure
Thumb
Synonyms
  • 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
  • Coumafene
  • Zoocoumarin
Product Ingredients
IngredientUNIICASInChI Key
Warfarin potassiumI47IU4FOCO2610-86-8WSHYKIAQCMIPTB-UHFFFAOYSA-M
Warfarin sodium6153CWM0CL129-06-6KYITYFHKDODNCQ-UHFFFAOYNA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CoumadinTablet10 mg/1OralRemedy Repack2013-04-012016-12-22Us
CoumadinTablet5 mg/1OralPhysicians Total Care, Inc.2004-11-15Not applicableUs
CoumadinTablet2 mg/1OralBristol Myers Squibb Pharma Company2009-01-01Not applicableUs
CoumadinTablet10 mg/1OralCardinal Health2009-01-01Not applicableUs
CoumadinTablet1 mg/1OralAvera Mc Kennan Hospital2016-07-15Not applicableUs
CoumadinTablet10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2009-01-01Not applicableUs
CoumadinTablet6 mg/1OralPhysicians Total Care, Inc.2005-03-23Not applicableUs
CoumadinTablet1 mg/1OralRemedy Repack2013-03-012016-12-24Us00056 0169 70 nlmimage10 931349aa
CoumadinPowder, for solution5 mgIntravenousBristol Myers Squibb1997-09-022006-05-29Canada
CoumadinTablet7.5 mg/1OralAphena Pharma Solutions Tennessee, Inc.2009-01-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-warfarinTablet10 mgOralApotex Corporation2000-10-16Not applicableCanada
Apo-warfarinTablet1 mgOralApotex Corporation2000-10-16Not applicableCanada
Apo-warfarinTablet4 mgOralApotex Corporation2000-10-16Not applicableCanada
Apo-warfarinTablet3 mgOralApotex Corporation2002-04-23Not applicableCanada
Apo-warfarinTablet2 mgOralApotex Corporation2000-10-16Not applicableCanada
Apo-warfarinTablet5 mgOralApotex Corporation2000-10-16Not applicableCanada
Apo-warfarinTablet2.5 mgOralApotex Corporation2000-10-16Not applicableCanada
JantovenTablet1 mg/1OralUpsher Smith Laboratories2010-02-23Not applicableUs
JantovenTablet4 mg/1OralRemedy Repack2013-05-172016-04-05Us
JantovenTablet10 mg/1OralUpsher Smith Laboratories2010-02-23Not applicableUs
International/Other Brands
Lawarin / Marevan / Waran / Warfant
Categories
UNII
5Q7ZVV76EI
CAS number
81-81-2
Weight
Average: 308.3279
Monoisotopic: 308.104859
Chemical Formula
C19H16O4
InChI Key
PJVWKTKQMONHTI-UHFFFAOYSA-N
InChI
InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
IUPAC Name
4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
SMILES
CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2

Pharmacology

Indication

For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.

Structured Indications
Pharmacodynamics

Warfarin, a coumarin anticoagulant, is a racemic mixture of two active isomers. It is used in the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).

Mechanism of action

Warfarin inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.

TargetActionsOrganism
AVitamin K epoxide reductase complex subunit 1
inhibitor
Human
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
Absorption

Rapidly absorbed following oral administration with considerable interindividual variations. Also absorbed percutaneously.

Volume of distribution
  • 0.14 L/kg
Protein binding

99% bound primarily to albumin

Metabolism

Metabolized stereo- and regio-selectively by hepatic microsomal enzymes. S-warfarin is predominantly metabolized by cytochrome P450 (CYP) 2C9 to yield the 6- and 7-hydroxylated metabolites. R-warfarin is metabolized by CYP1A1, 1A2, and 3A4 to yield 6-, 8-, and 10-hydroxylated metabolites. Hydroxylated metabolites may be further conjugated prior to excretion into bile and urine. UGT1A1 appears to be responsible for producing the 6-O-glucuronide of warfarin, with a possibly contribution from UGT1A10. Five UGT1As may be involved in the formation of 7-O-glucuronide warfarin. S-warfarin has higher potency than R-warfarin and genetic polymorphisms in CYP2C9 may dramatically decrease clearance of and increase toxicity of the medication.

Route of elimination

The elimination of warfarin is almost entirely by metabolism. Very little warfarin is excreted unchanged in urine. The metabolites are principally excreted into the urine; and to a lesser extent into the bile.

Half life

R-warfarin t1/2=37-89 hours; S-warfarin t1/2=21-43 hours.

Clearance
  • 0.065 +/- 0.025 mL/min/kg [CYP2C9 Genotype 1/1]
  • 0.041 +/- 0.021 [CYP2C9 Genotype 1/2 or 1/3]
  • 0.020 +/- 0.011 [CYP2C9 Genotype 2/2, 2/3, or 3/3]
Toxicity

LD50=374 (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Warfarin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*2(T;T) / (C;T)T AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of warfarin.Details
Vitamin K epoxide reductase complex subunit 1---(A;A) / (A;G)-1639G>AEffect Directly StudiedPatients with this genotype in VKORC1 are associated with reduced metabolism of warfarin and increased risk of serious bleeding thus require lower doses.Details
Phylloquinone omega-hydroxylase CYP4F2---(T;T)T Allele, homozygousEffect Directly StudiedPatients with this genotype in CP4F2 may require higer doses of warfarin to attain therapeutic anticoagulant activity.Details
Cytochrome P450 2C9CYP2C9*2(T;T) / (C;T)T AlleleEffect Directly StudiedThe presence of this polymorphism in CYP2C9 is associated with reduction in warfarin metabolism.Details
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleEffect Directly StudiedThe presence of this polymorphism in CYP2C9 is associated with reduction in warfarin metabolism.Details
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose recommended.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*3Not Available1075A>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the anticoagulant activities of Warfarin.Investigational
19-norandrostenedione19-norandrostenedione may increase the anticoagulant activities of Warfarin.Experimental, Illicit
5-androstenedione5-androstenedione may increase the anticoagulant activities of Warfarin.Experimental, Illicit
AbciximabAbciximab may increase the anticoagulant activities of Warfarin.Approved
AbirateroneThe serum concentration of Warfarin can be increased when it is combined with Abiraterone.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Warfarin.Approved
AcemetacinAcemetacin may increase the anticoagulant activities of Warfarin.Approved
AcenocoumarolWarfarin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenAcetaminophen may increase the anticoagulant activities of Warfarin.Approved
AcetohexamideAcetohexamide may increase the anticoagulant activities of Warfarin.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
AdalimumabThe serum concentration of Warfarin can be decreased when it is combined with Adalimumab.Approved
AdapaleneAdapalene may increase the anticoagulant activities of Warfarin.Approved
AlaproclateAlaproclate may increase the anticoagulant activities of Warfarin.Experimental
AlclofenacAlclofenac may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
AlclometasoneAlclometasone may increase the anticoagulant activities of Warfarin.Approved
AldosteroneAldosterone may increase the anticoagulant activities of Warfarin.Experimental
AllopurinolAllopurinol may increase the anticoagulant activities of Warfarin.Approved
AllylestrenolThe therapeutic efficacy of Warfarin can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Warfarin.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Warfarin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Warfarin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Warfarin.Approved
AltrenogestThe therapeutic efficacy of Warfarin can be decreased when used in combination with Altrenogest.Vet Approved
Aluminium clofibrateAluminium clofibrate may increase the anticoagulant activities of Warfarin.Experimental
ALX-0081ALX-0081 may increase the anticoagulant activities of Warfarin.Investigational
AmcinonideAmcinonide may increase the anticoagulant activities of Warfarin.Approved
AmdinocillinAmdinocillin may increase the anticoagulant activities of Warfarin.Withdrawn
AmineptineAmineptine may increase the anticoagulant activities of Warfarin.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Warfarin.Approved
AmiodaroneAmiodarone may increase the anticoagulant activities of Warfarin.Approved, Investigational
AmitriptylineAmitriptyline may increase the anticoagulant activities of Warfarin.Approved
AmobarbitalThe metabolism of Warfarin can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Warfarin.Approved
AmoxicillinAmoxicillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
AmpicillinAmpicillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Warfarin.Approved
AncrodWarfarin may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Warfarin.Investigational
AndrostenedioneAndrostenedione may increase the anticoagulant activities of Warfarin.Experimental, Illicit
AnecortaveAnecortave may increase the anticoagulant activities of Warfarin.Investigational
anecortave acetateanecortave acetate may increase the anticoagulant activities of Warfarin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Warfarin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Warfarin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Warfarin.Approved
Antithrombin III humanWarfarin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Warfarin.Approved
ApocyninApocynin may increase the anticoagulant activities of Warfarin.Investigational
ApremilastApremilast may increase the anticoagulant activities of Warfarin.Approved, Investigational
AprepitantThe serum concentration of Warfarin can be decreased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Warfarin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Warfarin.Approved, Investigational
ArmodafinilThe metabolism of Warfarin can be decreased when combined with Armodafinil.Approved, Investigational
AspoxicillinAspoxicillin may increase the anticoagulant activities of Warfarin.Experimental
AstaxanthinAstaxanthin may increase the anticoagulant activities of Warfarin.Investigational
AtamestaneAtamestane may increase the anticoagulant activities of Warfarin.Investigational
AtazanavirThe serum concentration of Warfarin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Warfarin can be decreased when combined with Atomoxetine.Approved
AtorvastatinAtorvastatin may increase the anticoagulant activities of Warfarin.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Warfarin.Withdrawn
AzathioprineAzathioprine may decrease the anticoagulant activities of Warfarin.Approved
AzelastineAzelastine may increase the anticoagulant activities of Warfarin.Approved
AzidocillinAzidocillin may increase the anticoagulant activities of Warfarin.Approved
AzithromycinThe metabolism of Warfarin can be decreased when combined with Azithromycin.Approved
AzlocillinAzlocillin may increase the anticoagulant activities of Warfarin.Approved
BacampicillinBacampicillin may increase the anticoagulant activities of Warfarin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Warfarin.Approved, Investigational
BarbexacloneThe metabolism of Warfarin can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Warfarin can be increased when combined with Barbital.Illicit
BatroxobinBatroxobin may increase the anticoagulant activities of Warfarin.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Warfarin.Approved, Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the anticoagulant activities of Warfarin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Warfarin.Approved
BendazacBendazac may increase the anticoagulant activities of Warfarin.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Warfarin.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Warfarin.Withdrawn
Benzathine benzylpenicillinBenzathine benzylpenicillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
BenzylpenicillinBenzylpenicillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
Benzylpenicilloyl PolylysineBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Warfarin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Warfarin.Investigational
BetamethasoneBetamethasone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
BevoniumBevonium may increase the anticoagulant activities of Warfarin.Experimental
BezafibrateBezafibrate may increase the anticoagulant activities of Warfarin.Approved
BicalutamideThe serum concentration of Warfarin can be increased when it is combined with Bicalutamide.Approved
BivalirudinBivalirudin may increase the anticoagulant activities of Warfarin.Approved, Investigational
BoceprevirThe serum concentration of Warfarin can be decreased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Warfarin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Warfarin can be increased when combined with Bosentan.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Warfarin.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Warfarin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Warfarin.Investigational
BudesonideBudesonide may increase the anticoagulant activities of Warfarin.Approved
BufexamacBufexamac may increase the anticoagulant activities of Warfarin.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Warfarin.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Warfarin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Warfarin.Investigational
CaffeineThe metabolism of Warfarin can be decreased when combined with Caffeine.Approved
CangrelorCangrelor may increase the anticoagulant activities of Warfarin.Approved
CapecitabineThe serum concentration of Warfarin can be increased when it is combined with Capecitabine.Approved, Investigational
CarbamazepineThe serum concentration of Warfarin can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Warfarin.Experimental
CarbenicillinCarbenicillin may increase the anticoagulant activities of Warfarin.Approved
Carbenicillin indanylCarbenicillin indanyl may increase the anticoagulant activities of Warfarin.Approved
CarbimazoleCarbimazole may decrease the anticoagulant activities of Warfarin.Approved
CarbomycinThe serum concentration of Warfarin can be increased when it is combined with Carbomycin.Vet Approved
CarbutamideCarbutamide may increase the anticoagulant activities of Warfarin.Experimental
CarfecillinCarfecillin may increase the anticoagulant activities of Warfarin.Experimental
CarprofenCarprofen may increase the anticoagulant activities of Warfarin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Warfarin.Experimental
CefacetrileCefacetrile may increase the anticoagulant activities of Warfarin.Approved
CefaclorCefaclor may increase the anticoagulant activities of Warfarin.Approved
CefadroxilCefadroxil may increase the anticoagulant activities of Warfarin.Approved, Vet Approved, Withdrawn
CefalotinCefalotin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
CefamandoleCefamandole may increase the anticoagulant activities of Warfarin.Approved
CefapirinCefapirin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
CefatrizineCefatrizine may increase the anticoagulant activities of Warfarin.Experimental
CefazedoneCefazedone may increase the anticoagulant activities of Warfarin.Experimental
CefazolinCefazolin may increase the anticoagulant activities of Warfarin.Approved
CefbuperazoneCefbuperazone may increase the anticoagulant activities of Warfarin.Experimental
CefetametCefetamet may increase the anticoagulant activities of Warfarin.Experimental
CefiximeCefixime may increase the anticoagulant activities of Warfarin.Approved
CefmenoximeCefmenoxime may increase the anticoagulant activities of Warfarin.Approved
CefmetazoleCefmetazole may increase the anticoagulant activities of Warfarin.Approved
CefminoxCefminox may increase the anticoagulant activities of Warfarin.Approved
CefodizimeCefodizime may increase the anticoagulant activities of Warfarin.Experimental
CefonicidCefonicid may increase the anticoagulant activities of Warfarin.Approved
CefoperazoneCefoperazone may increase the anticoagulant activities of Warfarin.Approved
CeforanideCeforanide may increase the anticoagulant activities of Warfarin.Approved
CefotaximeCefotaxime may increase the anticoagulant activities of Warfarin.Approved
CefotetanCefotetan may increase the anticoagulant activities of Warfarin.Approved
CefotiamCefotiam may increase the anticoagulant activities of Warfarin.Approved
CefoxitinCefoxitin may increase the anticoagulant activities of Warfarin.Approved
CefpodoximeCefpodoxime may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
CefradineCefradine may increase the anticoagulant activities of Warfarin.Approved
CefroxadineCefroxadine may increase the anticoagulant activities of Warfarin.Withdrawn
CefsulodinCefsulodin may increase the anticoagulant activities of Warfarin.Experimental
CeftazidimeCeftazidime may increase the anticoagulant activities of Warfarin.Approved
CeftezoleCeftezole may increase the anticoagulant activities of Warfarin.Experimental
CeftizoximeCeftizoxime may increase the anticoagulant activities of Warfarin.Approved
CeftriaxoneCeftriaxone may increase the anticoagulant activities of Warfarin.Approved
CefuroximeCefuroxime may increase the anticoagulant activities of Warfarin.Approved
CelecoxibCelecoxib may increase the anticoagulant activities of Warfarin.Approved, Investigational
CephalexinCephalexin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
CephaloglycinCephaloglycin may increase the anticoagulant activities of Warfarin.Approved
CephaloridineCephaloridine may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
CeritinibThe serum concentration of Warfarin can be increased when it is combined with Ceritinib.Approved
CerivastatinCerivastatin may increase the anticoagulant activities of Warfarin.Withdrawn
CertoparinWarfarin may increase the anticoagulant activities of Certoparin.Approved
Chloral hydrateThe serum concentration of Warfarin can be increased when it is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolChloramphenicol may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
ChloroquineChloroquine may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Warfarin.Withdrawn
ChlorpropamideChlorpropamide may increase the anticoagulant activities of Warfarin.Approved
ChlortetracyclineChlortetracycline may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
CholecalciferolThe metabolism of Warfarin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Warfarin.Approved
Chondroitin sulfateChondroitin sulfate may increase the anticoagulant activities of Warfarin.Nutraceutical
CiclesonideCiclesonide may increase the anticoagulant activities of Warfarin.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Warfarin.Approved
CimetidineCimetidine may increase the anticoagulant activities of Warfarin.Approved
CinoxacinCinoxacin may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
CiprofibrateCiprofibrate may increase the anticoagulant activities of Warfarin.Approved
CitalopramThe metabolism of Warfarin can be decreased when combined with Citalopram.Approved
Citric AcidWarfarin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Warfarin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Warfarin can be decreased when combined with Clemastine.Approved
ClobetasolClobetasol may increase the anticoagulant activities of Warfarin.Investigational
Clobetasol propionateClobetasol propionate may increase the anticoagulant activities of Warfarin.Approved
ClobetasoneClobetasone may increase the anticoagulant activities of Warfarin.Approved
ClocortoloneClocortolone may increase the anticoagulant activities of Warfarin.Approved
ClofibrateClofibrate may increase the anticoagulant activities of Warfarin.Approved
ClofibrideClofibride may increase the anticoagulant activities of Warfarin.Experimental
ClomipramineClomipramine may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Warfarin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Warfarin.Approved, Nutraceutical
CloricromenCloricromen may increase the anticoagulant activities of Warfarin.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Warfarin.Experimental
ClotrimazoleThe metabolism of Warfarin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxacillinCloxacillin may decrease the anticoagulant activities of Warfarin.Approved, Vet Approved
CobicistatThe serum concentration of Warfarin can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Warfarin is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Warfarin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Warfarin.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the anticoagulant activities of Warfarin.Investigational
CorticosteroneCorticosterone may increase the anticoagulant activities of Warfarin.Experimental
Cortisone acetateCortisone acetate may increase the anticoagulant activities of Warfarin.Approved
CranberryCranberry may increase the anticoagulant activities of Warfarin.Approved
CrisaboroleThe metabolism of Warfarin can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Warfarin can be decreased when combined with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Warfarin.Investigational
CyclacillinCyclacillin may increase the anticoagulant activities of Warfarin.Approved
CyclobenzaprineCyclobenzaprine may increase the anticoagulant activities of Warfarin.Approved
CyclosporineThe metabolism of Warfarin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Warfarin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Warfarin.Investigational
DabrafenibThe serum concentration of Warfarin can be decreased when it is combined with Dabrafenib.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Warfarin.Experimental
DalteparinWarfarin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidWarfarin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the anticoagulant activities of Warfarin.Investigational
DarexabanWarfarin may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe serum concentration of Warfarin can be decreased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Warfarin.Approved, Investigational
DeferasiroxThe serum concentration of Warfarin can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Warfarin.Approved, Investigational
DelavirdineThe metabolism of Warfarin can be decreased when combined with Delavirdine.Approved
DemeclocyclineDemeclocycline may increase the anticoagulant activities of Warfarin.Approved
DemegestoneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Warfarin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Warfarin.Investigational
DesipramineDesipramine may increase the anticoagulant activities of Warfarin.Approved
DesirudinWarfarin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Warfarin.Investigational
DesogestrelDesogestrel may decrease the anticoagulant activities of Warfarin.Approved
DesoximetasoneDesoximetasone may increase the anticoagulant activities of Warfarin.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the anticoagulant activities of Warfarin.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the anticoagulant activities of Warfarin.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Warfarin.Approved
DexamethasoneDexamethasone may increase the anticoagulant activities of Warfarin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the anticoagulant activities of Warfarin.Vet Approved
DexmethylphenidateThe serum concentration of Warfarin can be increased when it is combined with Dexmethylphenidate.Approved
DextranWarfarin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Warfarin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Warfarin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Warfarin may increase the anticoagulant activities of Dextran 75.Approved
DibenzepinDibenzepin may increase the anticoagulant activities of Warfarin.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
DicloxacillinDicloxacillin may decrease the anticoagulant activities of Warfarin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Warfarin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Warfarin.Approved
DienogestDienogest may decrease the anticoagulant activities of Warfarin.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Warfarin.Approved
DifenpiramideDifenpiramide may increase the anticoagulant activities of Warfarin.Experimental
DiflorasoneDiflorasone may increase the anticoagulant activities of Warfarin.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Warfarin.Approved
DifluocortoloneDifluocortolone may increase the anticoagulant activities of Warfarin.Approved
DifluprednateDifluprednate may increase the anticoagulant activities of Warfarin.Approved
DihydroergotamineThe metabolism of Warfarin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the anticoagulant activities of Warfarin.Illicit
DiltiazemThe metabolism of Warfarin can be decreased when combined with Diltiazem.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Warfarin.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Warfarin.Approved
DisulfiramThe serum concentration of Warfarin can be increased when it is combined with Disulfiram.Approved
DitazoleDitazole may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
DosulepinThe metabolism of Warfarin can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the anticoagulant activities of Warfarin.Approved
DoxycyclineThe metabolism of Warfarin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Warfarin can be increased when it is combined with Dronedarone.Approved
DrospirenoneDrospirenone may decrease the anticoagulant activities of Warfarin.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Warfarin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Warfarin.Approved
DuloxetineDuloxetine may increase the anticoagulant activities of Warfarin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Warfarin.Investigational
DydrogesteroneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Warfarin.Investigational
EconazoleThe serum concentration of Warfarin can be increased when it is combined with Econazole.Approved
Edetic AcidWarfarin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Warfarin.Approved
EfavirenzThe serum concentration of Warfarin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElvitegravirThe serum concentration of Warfarin can be decreased when it is combined with Elvitegravir.Approved
EnoxacinEnoxacin may increase the anticoagulant activities of Warfarin.Approved
EnoxaparinWarfarin may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Warfarin can be decreased when it is combined with Enzalutamide.Approved
EpicillinEpicillin may increase the anticoagulant activities of Warfarin.Experimental
EpimestrolEpimestrol may decrease the anticoagulant activities of Warfarin.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Warfarin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Warfarin.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Warfarin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Warfarin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Warfarin.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Warfarin.Approved, Investigational
EquileninEquilenin may increase the anticoagulant activities of Warfarin.Experimental
EquilinEquilin may increase the anticoagulant activities of Warfarin.Approved
EquolEquol may decrease the anticoagulant activities of Warfarin.Investigational
ErlotinibThe serum concentration of Warfarin can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Warfarin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the anticoagulant activities of Warfarin.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Warfarin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may increase the anticoagulant activities of Warfarin.Investigational
EsomeprazoleThe serum concentration of Warfarin can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Warfarin.Approved, Investigational, Vet Approved
EstramustineEstramustine may decrease the anticoagulant activities of Warfarin.Approved
EstriolEstriol may decrease the anticoagulant activities of Warfarin.Approved, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Warfarin.Approved
EstroneEstrone may increase the anticoagulant activities of Warfarin.Approved
Estrone sulfateEstrone sulfate may increase the anticoagulant activities of Warfarin.Approved
Etacrynic acidThe serum concentration of Warfarin can be increased when it is combined with Etacrynic acid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Warfarin.Approved, Investigational
EthanolThe serum concentration of Warfarin can be decreased when it is combined with Ethanol.Approved
EthenzamideEthenzamide may increase the anticoagulant activities of Warfarin.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Warfarin.Approved
EthotoinEthotoin may increase the anticoagulant activities of Warfarin.Approved
Ethyl biscoumacetateWarfarin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateEthynodiol diacetate may decrease the anticoagulant activities of Warfarin.Approved
EtodolacEtodolac may increase the anticoagulant activities of Warfarin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Warfarin.Approved
EtofibrateEtofibrate may increase the anticoagulant activities of Warfarin.Approved
EtonogestrelEtonogestrel may decrease the anticoagulant activities of Warfarin.Approved, Investigational
EtoperidoneEtoperidone may increase the anticoagulant activities of Warfarin.Approved
EtoposideEtoposide may increase the anticoagulant activities of Warfarin.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Warfarin.Approved, Investigational
EtravirineThe metabolism of Warfarin can be decreased when combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Warfarin.Approved
ExenatideExenatide may increase the anticoagulant activities of Warfarin.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Warfarin.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Warfarin.Experimental
FelodipineThe metabolism of Warfarin can be decreased when combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Warfarin.Approved
FenofibrateFenofibrate may increase the anticoagulant activities of Warfarin.Approved
Fenofibric acidFenofibric acid may increase the anticoagulant activities of Warfarin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Warfarin.Approved
FentiazacFentiazac may increase the anticoagulant activities of Warfarin.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Warfarin.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Warfarin.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Warfarin.Investigational
FleroxacinFleroxacin may increase the anticoagulant activities of Warfarin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
FloxuridineThe metabolism of Warfarin can be decreased when combined with Floxuridine.Approved
fluasteronefluasterone may increase the anticoagulant activities of Warfarin.Investigational
FlucloxacillinFlucloxacillin may decrease the anticoagulant activities of Warfarin.Approved
FluconazoleThe serum concentration of Warfarin can be increased when it is combined with Fluconazole.Approved
FludrocortisoneFludrocortisone may increase the anticoagulant activities of Warfarin.Approved
FluindioneWarfarin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the anticoagulant activities of Warfarin.Withdrawn
FlumethasoneFlumethasone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
FlunixinFlunixin may increase the anticoagulant activities of Warfarin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Warfarin.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the anticoagulant activities of Warfarin.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the anticoagulant activities of Warfarin.Approved, Investigational
FluocortoloneFluocortolone may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
FluorometholoneFluorometholone may increase the anticoagulant activities of Warfarin.Approved
FluorouracilThe serum concentration of Warfarin can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe metabolism of Warfarin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the anticoagulant activities of Warfarin.Approved, Illicit
FluprednideneFluprednidene may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the anticoagulant activities of Warfarin.Approved
FlurandrenolideFlurandrenolide may increase the anticoagulant activities of Warfarin.Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Warfarin.Approved, Investigational
FluvastatinThe metabolism of Warfarin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Warfarin can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxWarfarin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Warfarin.Approved, Investigational
FormestaneFormestane may increase the anticoagulant activities of Warfarin.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Warfarin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Warfarin can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the anticoagulant activities of Warfarin.Approved
GabexateWarfarin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinGarenoxacin may increase the anticoagulant activities of Warfarin.Investigational
GatifloxacinGatifloxacin may increase the anticoagulant activities of Warfarin.Approved, Investigational
GefitinibGefitinib may increase the anticoagulant activities of Warfarin.Approved, Investigational
GemcitabineGemcitabine may increase the anticoagulant activities of Warfarin.Approved
GemfibrozilThe metabolism of Warfarin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the anticoagulant activities of Warfarin.Approved, Investigational
GenisteinGenistein may decrease the anticoagulant activities of Warfarin.Investigational
GestodeneGestodene may decrease the anticoagulant activities of Warfarin.Approved
GestonoroneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Gestrinone.Approved
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Warfarin.Approved, Nutraceutical
GlibornurideGlibornuride may increase the anticoagulant activities of Warfarin.Withdrawn
GliclazideGliclazide may increase the anticoagulant activities of Warfarin.Approved
GlipizideGlipizide may increase the anticoagulant activities of Warfarin.Approved
GliquidoneGliquidone may increase the anticoagulant activities of Warfarin.Approved
GlisoxepideGlisoxepide may increase the anticoagulant activities of Warfarin.Approved
GLPG-0492GLPG-0492 may increase the anticoagulant activities of Warfarin.Investigational
Glucagon recombinantGlucagon recombinant may increase the anticoagulant activities of Warfarin.Approved
GlucosamineGlucosamine may increase the anticoagulant activities of Warfarin.Approved
GlutethimideThe metabolism of Warfarin can be increased when combined with Glutethimide.Approved, Illicit
GlyburideGlyburide may increase the anticoagulant activities of Warfarin.Approved
GrepafloxacinGrepafloxacin may increase the anticoagulant activities of Warfarin.Withdrawn
GriseofulvinThe serum concentration of Warfarin can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Warfarin.Experimental
HE3286HE3286 may increase the anticoagulant activities of Warfarin.Investigational
HeminHemin may increase the anticoagulant activities of Warfarin.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Warfarin.Experimental
HeparinWarfarin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Warfarin.Withdrawn
HexobarbitalThe metabolism of Warfarin can be increased when combined with Hexobarbital.Approved
HigenamineHigenamine may increase the anticoagulant activities of Warfarin.Investigational
HydrocortisoneHydrocortisone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Warfarin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Warfarin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Warfarin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Warfarin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Warfarin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Warfarin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Warfarin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Warfarin.Approved, Nutraceutical
IdelalisibThe serum concentration of Warfarin can be increased when it is combined with Idelalisib.Approved
IdraparinuxWarfarin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Warfarin.Investigational
IfosfamideIfosfamide may increase the anticoagulant activities of Warfarin.Approved
IloprostIloprost may increase the anticoagulant activities of Warfarin.Approved, Investigational
ImatinibImatinib may increase the anticoagulant activities of Warfarin.Approved
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Warfarin.Experimental
ImipramineImipramine may increase the anticoagulant activities of Warfarin.Approved
IndalpineIndalpine may increase the anticoagulant activities of Warfarin.Investigational, Withdrawn
IndinavirThe metabolism of Warfarin can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Warfarin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Warfarin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Warfarin.Withdrawn
IprindoleIprindole may increase the anticoagulant activities of Warfarin.Experimental
IrbesartanThe metabolism of Warfarin can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Warfarin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Warfarin can be decreased when combined with Isoniazid.Approved
IsoxicamIsoxicam may increase the anticoagulant activities of Warfarin.Withdrawn
IsradipineThe metabolism of Warfarin can be decreased when combined with Isradipine.Approved
IstaroximeIstaroxime may increase the anticoagulant activities of Warfarin.Investigational
ItraconazoleThe serum concentration of Warfarin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Warfarin can be increased when it is combined with Ivacaftor.Approved
IvermectinIvermectin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
JosamycinThe serum concentration of Warfarin can be increased when it is combined with Josamycin.Approved
KebuzoneKebuzone may increase the anticoagulant activities of Warfarin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Warfarin.Investigational
KetoconazoleThe serum concentration of Warfarin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Warfarin.Approved
KitasamycinThe serum concentration of Warfarin can be increased when it is combined with Kitasamycin.Experimental
L-CarnitineL-Carnitine may increase the anticoagulant activities of Warfarin.Approved
LansoprazoleThe serum concentration of Warfarin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe metabolism of Warfarin can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Warfarin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Warfarin.Approved
LetaxabanWarfarin may increase the anticoagulant activities of Letaxaban.Investigational
LevofloxacinLevofloxacin may increase the anticoagulant activities of Warfarin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Warfarin.Approved
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Warfarin.Approved, Investigational
LevothyroxineLevothyroxine may increase the anticoagulant activities of Warfarin.Approved
LidocaineThe metabolism of Warfarin can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Warfarin.Approved
LinsidomineLinsidomine may increase the anticoagulant activities of Warfarin.Experimental
LiothyronineLiothyronine may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
LiotrixLiotrix may increase the anticoagulant activities of Warfarin.Approved
LisofyllineLisofylline may increase the anticoagulant activities of Warfarin.Investigational
LixisenatideLixisenatide can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LobeglitazoneThe metabolism of Warfarin can be decreased when combined with Lobeglitazone.Approved
LofepramineLofepramine may increase the anticoagulant activities of Warfarin.Experimental
LomitapideThe serum concentration of Warfarin can be increased when it is combined with Lomitapide.Approved
LonazolacLonazolac may increase the anticoagulant activities of Warfarin.Experimental
LopinavirThe serum concentration of Warfarin can be decreased when it is combined with Lopinavir.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Warfarin.Approved
LosartanThe metabolism of Warfarin can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Warfarin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Warfarin.Approved
LuliconazoleThe serum concentration of Warfarin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Warfarin can be increased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Warfarin.Approved, Investigational
LynestrenolLynestrenol may decrease the anticoagulant activities of Warfarin.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Warfarin.Approved
ManidipineThe metabolism of Warfarin can be decreased when combined with Manidipine.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Warfarin.Approved
ME-609ME-609 may increase the anticoagulant activities of Warfarin.Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateMedroxyprogesterone acetate may decrease the anticoagulant activities of Warfarin.Approved, Investigational
MedrysoneMedrysone may increase the anticoagulant activities of Warfarin.Approved
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Warfarin.Approved
MelagatranWarfarin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolMelengestrol may increase the anticoagulant activities of Warfarin.Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
MercaptopurineMercaptopurine may decrease the anticoagulant activities of Warfarin.Approved
MesalazineMesalazine may increase the anticoagulant activities of Warfarin.Approved
MesteroloneMesterolone may increase the anticoagulant activities of Warfarin.Experimental
MestranolMestranol may decrease the anticoagulant activities of Warfarin.Approved
MetahexamideMetahexamide may increase the anticoagulant activities of Warfarin.Experimental
MetamizoleMetamizole may increase the anticoagulant activities of Warfarin.Withdrawn
MetampicillinMetampicillin may increase the anticoagulant activities of Warfarin.Experimental
MethallenestrilMethallenestril may decrease the anticoagulant activities of Warfarin.Experimental
MethimazoleMethimazole may decrease the anticoagulant activities of Warfarin.Approved
MethohexitalThe metabolism of Warfarin can be increased when combined with Methohexital.Approved
MethylestrenoloneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Methylestrenolone.Experimental
MethylphenidateThe serum concentration of Warfarin can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Warfarin can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneMethylprednisolone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the anticoagulant activities of Warfarin.Approved
MethylthiouracilMethylthiouracil may decrease the anticoagulant activities of Warfarin.Experimental
MeticillinMeticillin may increase the anticoagulant activities of Warfarin.Approved
MetreleptinThe serum concentration of Warfarin can be decreased when it is combined with Metreleptin.Approved
MetronidazoleThe serum concentration of Warfarin can be increased when it is combined with Metronidazole.Approved
MevastatinMevastatin may increase the anticoagulant activities of Warfarin.Experimental
MexiletineThe metabolism of Warfarin can be decreased when combined with Mexiletine.Approved
MezlocillinMezlocillin may increase the anticoagulant activities of Warfarin.Approved
MidostaurinThe metabolism of Warfarin can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Warfarin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Warfarin.Approved
MilrinoneMilrinone may increase the anticoagulant activities of Warfarin.Approved
MinocyclineMinocycline may increase the anticoagulant activities of Warfarin.Approved, Investigational
MirtazapineMirtazapine may increase the anticoagulant activities of Warfarin.Approved
MitotaneThe serum concentration of Warfarin can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may increase the anticoagulant activities of Warfarin.Investigational
MoclobemideThe metabolism of Warfarin can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Warfarin can be decreased when combined with Modafinil.Approved, Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Warfarin.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Warfarin.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Warfarin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Warfarin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Warfarin.Approved
NadroparinWarfarin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Warfarin.Approved, Investigational
NafcillinNafcillin may decrease the anticoagulant activities of Warfarin.Approved
NaftifineNaftifine may increase the anticoagulant activities of Warfarin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Warfarin.Investigational
Nalidixic AcidNalidixic Acid may increase the anticoagulant activities of Warfarin.Approved
NandroloneNandrolone may increase the anticoagulant activities of Warfarin.Experimental
NaproxenNaproxen may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
NCX 1022NCX 1022 may increase the anticoagulant activities of Warfarin.Investigational
NefazodoneThe metabolism of Warfarin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Warfarin can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the anticoagulant activities of Warfarin.Investigational
NeomycinNeomycin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Warfarin.Approved
NetupitantThe serum concentration of Warfarin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Warfarin can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Warfarin can be decreased when combined with Nicardipine.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Warfarin.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Warfarin.Approved
NilotinibThe metabolism of Warfarin can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Warfarin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Warfarin.Investigational
NomegestrolThe therapeutic efficacy of Warfarin can be decreased when used in combination with Nomegestrol.Approved
NorelgestrominNorelgestromin may decrease the anticoagulant activities of Warfarin.Approved
NorethisteroneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the anticoagulant activities of Warfarin.Approved
NorgestimateNorgestimate may decrease the anticoagulant activities of Warfarin.Approved
NorgestrelNorgestrel may decrease the anticoagulant activities of Warfarin.Approved
NorgestrienoneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineNortriptyline may increase the anticoagulant activities of Warfarin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Warfarin is combined with Obinutuzumab.Approved
OlaparibThe metabolism of Warfarin can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Warfarin can be increased when it is combined with Oleandomycin.Vet Approved
Oleoyl-estroneOleoyl-estrone may increase the anticoagulant activities of Warfarin.Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Warfarin.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Warfarin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Warfarin is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Warfarin.Approved, Nutraceutical
OmeprazoleThe serum concentration of Warfarin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolOpipramol may increase the anticoagulant activities of Warfarin.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Warfarin.Vet Approved
OritavancinThe serum concentration of Warfarin can be increased when it is combined with Oritavancin.Approved, Investigational
OrlistatOrlistat may increase the anticoagulant activities of Warfarin.Approved, Investigational
OsimertinibThe serum concentration of Warfarin can be increased when it is combined with Osimertinib.Approved
OtamixabanWarfarin may increase the anticoagulant activities of Otamixaban.Investigational
OxacillinOxacillin may increase the anticoagulant activities of Warfarin.Approved
OxandroloneOxandrolone may increase the anticoagulant activities of Warfarin.Approved, Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Warfarin.Approved
Oxolinic acidOxolinic acid may increase the anticoagulant activities of Warfarin.Experimental
OxymetholoneOxymetholone may increase the anticoagulant activities of Warfarin.Approved, Illicit
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Warfarin.Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Warfarin.Investigational
PalbociclibThe serum concentration of Warfarin can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Warfarin can be decreased when combined with Pantoprazole.Approved
ParamethasoneParamethasone may increase the anticoagulant activities of Warfarin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Warfarin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Warfarin.Approved
ParoxetineParoxetine may increase the anticoagulant activities of Warfarin.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Warfarin.Investigational
PazufloxacinPazufloxacin may increase the anticoagulant activities of Warfarin.Investigational
PefloxacinPefloxacin may increase the anticoagulant activities of Warfarin.Approved
Peginterferon alfa-2bThe serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.Approved
PenamecillinPenamecillin may increase the anticoagulant activities of Warfarin.Experimental
PenimepicyclinePenimepicycline may increase the anticoagulant activities of Warfarin.Experimental
PentobarbitalThe metabolism of Warfarin can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Warfarin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Warfarin.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Warfarin.Approved
PhenobarbitalThe metabolism of Warfarin can be increased when combined with Phenobarbital.Approved
PhenoxymethylpenicillinPhenoxymethylpenicillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
PhenprocoumonWarfarin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
PhenytoinPhenytoin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
PhylloquinonePhylloquinone may decrease the anticoagulant activities of Warfarin.Approved
PicotamidePicotamide may increase the anticoagulant activities of Warfarin.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Warfarin.Approved, Investigational
PioglitazoneThe metabolism of Warfarin can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidPipemidic acid may increase the anticoagulant activities of Warfarin.Experimental
PiperacillinPiperacillin may increase the anticoagulant activities of Warfarin.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Warfarin.Investigational
Piromidic acidPiromidic acid may increase the anticoagulant activities of Warfarin.Experimental
PiroxicamPiroxicam may increase the anticoagulant activities of Warfarin.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Warfarin.Experimental
PitavastatinPitavastatin may increase the anticoagulant activities of Warfarin.Approved
PivampicillinPivampicillin may increase the anticoagulant activities of Warfarin.Approved
PivmecillinamPivmecillinam may increase the anticoagulant activities of Warfarin.Approved
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Warfarin.Approved
PosaconazoleThe serum concentration of Warfarin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Warfarin.Experimental
PrasteronePrasterone may increase the anticoagulant activities of Warfarin.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the anticoagulant activities of Warfarin.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Warfarin.Approved
PravastatinPravastatin may increase the anticoagulant activities of Warfarin.Approved
PrednicarbatePrednicarbate may increase the anticoagulant activities of Warfarin.Approved
PrednisolonePrednisolone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
PrednisonePrednisone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
PregnenolonePregnenolone may increase the anticoagulant activities of Warfarin.Experimental
PrimidoneThe metabolism of Warfarin can be increased when combined with Primidone.Approved, Vet Approved
Procaine benzylpenicillinProcaine benzylpenicillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Warfarin.Experimental
ProguanilProguanil may increase the anticoagulant activities of Warfarin.Approved
PromegestoneThe therapeutic efficacy of Warfarin can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Warfarin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Warfarin.Approved
PropafenoneThe serum concentration of Warfarin can be increased when it is combined with Propafenone.Approved
PropicillinPropicillin may increase the anticoagulant activities of Warfarin.Experimental
PropylthiouracilPropylthiouracil may decrease the anticoagulant activities of Warfarin.Approved
PropyphenazonePropyphenazone may increase the anticoagulant activities of Warfarin.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Warfarin.Experimental
Protein CWarfarin may increase the anticoagulant activities of Protein C.Approved
Protein S humanWarfarin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeWarfarin may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the anticoagulant activities of Warfarin.Approved
PrulifloxacinPrulifloxacin may increase the anticoagulant activities of Warfarin.Investigational
PTC299PTC299 may increase the anticoagulant activities of Warfarin.Investigational
PyrimethamineThe metabolism of Warfarin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Warfarin.Approved
QuinidineQuinidine may increase the anticoagulant activities of Warfarin.Approved
QuinineQuinine may increase the anticoagulant activities of Warfarin.Approved
RabeprazoleThe metabolism of Warfarin can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Warfarin.Investigational
RanitidineThe serum concentration of Warfarin can be increased when it is combined with Ranitidine.Approved
RanolazineThe metabolism of Warfarin can be decreased when combined with Ranolazine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Warfarin is combined with Regorafenib.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Warfarin.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Warfarin.Approved
ReviparinWarfarin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Warfarin.Approved
RifabutinThe metabolism of Warfarin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Warfarin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Warfarin can be increased when combined with Rifapentine.Approved
RimexoloneRimexolone may increase the anticoagulant activities of Warfarin.Approved
RitonavirThe serum concentration of Warfarin can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanWarfarin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Warfarin.Investigational, Withdrawn
RomidepsinRomidepsin may increase the anticoagulant activities of Warfarin.Approved, Investigational
RonifibrateRonifibrate may increase the anticoagulant activities of Warfarin.Experimental
RopiniroleThe metabolism of Warfarin can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Warfarin.Approved, Investigational
RosoxacinRosoxacin may increase the anticoagulant activities of Warfarin.Approved
RosuvastatinRosuvastatin may increase the anticoagulant activities of Warfarin.Approved
RufloxacinRufloxacin may increase the anticoagulant activities of Warfarin.Experimental
SalicylamideSalicylamide may increase the anticoagulant activities of Warfarin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Warfarin.Approved
SaquinavirThe serum concentration of Warfarin can be increased when it is combined with Saquinavir.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Warfarin.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Warfarin.Experimental
SecobarbitalThe metabolism of Warfarin can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Warfarin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Warfarin.Approved
SemapimodSemapimod may increase the anticoagulant activities of Warfarin.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Warfarin.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Warfarin.Investigational
SertralineThe metabolism of Warfarin can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
SildenafilThe metabolism of Warfarin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Warfarin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Warfarin can be increased when it is combined with Simeprevir.Approved
SimfibrateSimfibrate may increase the anticoagulant activities of Warfarin.Experimental
SimvastatinSimvastatin may increase the anticoagulant activities of Warfarin.Approved
SitafloxacinSitafloxacin may increase the anticoagulant activities of Warfarin.Experimental
SitaxentanThe serum concentration of Warfarin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
SolithromycinThe serum concentration of Warfarin can be increased when it is combined with Solithromycin.Investigational
SorafenibSorafenib may increase the anticoagulant activities of Warfarin.Approved, Investigational
SparfloxacinSparfloxacin may increase the anticoagulant activities of Warfarin.Approved
SRT501SRT501 may increase the anticoagulant activities of Warfarin.Investigational
St. John's WortThe metabolism of Warfarin can be increased when combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
StiripentolThe serum concentration of Warfarin can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the anticoagulant activities of Warfarin.Approved
SucralfateSucralfate may decrease the anticoagulant activities of Warfarin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Warfarin.Approved
SulbactamSulbactam may increase the anticoagulant activities of Warfarin.Approved
SulbenicillinSulbenicillin may increase the anticoagulant activities of Warfarin.Experimental
SulfadiazineThe metabolism of Warfarin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the anticoagulant activities of Warfarin.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Warfarin.Approved
SulfinpyrazoneThe metabolism of Warfarin can be decreased when combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Warfarin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Warfarin.Approved
SulodexideWarfarin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SultamicillinSultamicillin may increase the anticoagulant activities of Warfarin.Investigational
SuprofenSuprofen may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Warfarin.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Warfarin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Warfarin.Approved
TalampicillinTalampicillin may increase the anticoagulant activities of Warfarin.Experimental
TamoxifenThe serum concentration of Warfarin can be increased when it is combined with Tamoxifen.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Warfarin.Investigational
TazobactamTazobactam may increase the anticoagulant activities of Warfarin.Approved
TegafurThe serum concentration of Warfarin can be increased when it is combined with Tegafur.Approved
TelaprevirThe serum concentration of Warfarin can be decreased when it is combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Warfarin can be decreased when combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the anticoagulant activities of Warfarin.Withdrawn
TenecteplaseTenecteplase may increase the anticoagulant activities of Warfarin.Approved
TenidapTenidap may increase the anticoagulant activities of Warfarin.Experimental
Tenofovir disoproxilThe metabolism of Warfarin can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may increase the anticoagulant activities of Warfarin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Warfarin.Vet Approved
TeriflunomideThe serum concentration of Warfarin can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Warfarin.Investigational
TestosteroneTestosterone may increase the anticoagulant activities of Warfarin.Approved, Investigational
TheophyllineThe metabolism of Warfarin can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Warfarin can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Warfarin can be increased when combined with Thiopental.Approved, Vet Approved
Thyroid, porcineThyroid, porcine may increase the anticoagulant activities of Warfarin.Approved
TianeptineTianeptine may increase the anticoagulant activities of Warfarin.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Warfarin.Approved
TiboloneTibolone may increase the anticoagulant activities of Warfarin.Approved
TicagrelorThe metabolism of Warfarin can be decreased when combined with Ticagrelor.Approved
TicarcillinTicarcillin may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
TiclopidineThe metabolism of Warfarin can be decreased when combined with Ticlopidine.Approved
TigecyclineThe serum concentration of Warfarin can be increased when it is combined with Tigecycline.Approved
TinoridineTinoridine may increase the anticoagulant activities of Warfarin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Warfarin.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Warfarin.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Warfarin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Warfarin.Approved
TixocortolTixocortol may increase the anticoagulant activities of Warfarin.Approved
TocilizumabThe serum concentration of Warfarin can be decreased when it is combined with Tocilizumab.Approved
TolazamideTolazamide may increase the anticoagulant activities of Warfarin.Approved
TolbutamideThe metabolism of Warfarin can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Warfarin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Warfarin.Approved
TolterodineTolterodine may increase the anticoagulant activities of Warfarin.Approved, Investigational
TopiramateThe metabolism of Warfarin can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Warfarin can be decreased when combined with Topiroxostat.Approved
TorasemideThe serum concentration of Warfarin can be increased when it is combined with Torasemide.Approved
ToremifeneToremifene may increase the anticoagulant activities of Warfarin.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Warfarin is combined with Tositumomab.Approved
TramadolTramadol may increase the anticoagulant activities of Warfarin.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Warfarin.Approved, Investigational
TranylcypromineThe metabolism of Warfarin can be decreased when combined with Tranylcypromine.Approved
TrapidilTrapidil may increase the anticoagulant activities of Warfarin.Approved
TrazodoneTrazodone may decrease the anticoagulant activities of Warfarin.Approved, Investigational
TreprostinilTreprostinil may increase the anticoagulant activities of Warfarin.Approved, Investigational
TriamcinoloneTriamcinolone may increase the anticoagulant activities of Warfarin.Approved, Vet Approved
TribenosideTribenoside may increase the anticoagulant activities of Warfarin.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Warfarin.Approved
TrimethoprimThe metabolism of Warfarin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the anticoagulant activities of Warfarin.Approved
TriptolideTriptolide may increase the anticoagulant activities of Warfarin.Investigational
TrovafloxacinTrovafloxacin may increase the anticoagulant activities of Warfarin.Approved, Withdrawn
TroxerutinWarfarin may increase the anticoagulant activities of Troxerutin.Investigational
TylosinThe serum concentration of Warfarin can be increased when it is combined with Tylosin.Vet Approved
UbidecarenoneUbidecarenone may decrease the anticoagulant activities of Warfarin.Experimental
UrokinaseUrokinase may increase the anticoagulant activities of Warfarin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Warfarin.Investigational, Withdrawn
Valproic AcidThe metabolism of Warfarin can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Warfarin can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Warfarin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Warfarin.Approved
VerapamilThe metabolism of Warfarin can be decreased when combined with Verapamil.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Warfarin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Warfarin.Approved
VoriconazoleThe serum concentration of Warfarin can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the anticoagulant activities of Warfarin.Approved, Investigational
XimelagatranWarfarin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe serum concentration of Warfarin can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Warfarin.Approved
ZeranolZeranol may decrease the anticoagulant activities of Warfarin.Vet Approved
ZileutonThe serum concentration of Warfarin can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the anticoagulant activities of Warfarin.Withdrawn
ZiprasidoneThe metabolism of Warfarin can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Warfarin.Withdrawn
ZucapsaicinThe metabolism of Warfarin can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Avoid St. John's Wort.
  • Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables).
  • Limit garlic, ginger, gingko, and horse chestnut.

References

Synthesis Reference

Nasri W. Badran, "Microcrystalline 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin (warfarin) and methods of making." U.S. Patent US4113744, issued April, 1960.

US4113744
General References
  1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):204S-233S. [PubMed:15383473]
  2. Whitlon DS, Sadowski JA, Suttie JW: Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978 Apr 18;17(8):1371-7. [PubMed:646989]
  3. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature. 2004 Feb 5;427(6974):541-4. [PubMed:14765195]
  4. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41. [PubMed:14765194]
  5. Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003 May 7;41(9):1633-52. [PubMed:12742309]
  6. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005 May 23;165(10):1095-106. [PubMed:15911722]
  7. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670. [PubMed:18574265]
  8. Freedman MD: Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. [PubMed:1564123]
  9. Warfarin. (2007). In Human Developmental Toxicants: Aspects of Toxicology and Chemistry (pp. 193–4). CRC Press. [ISBN:1420006754]
  10. Loftus, Christopher M. (1995). Fetal toxicity of common neurosurgical drugs. In Neurosurgical Aspects of Pregnancy (pp. 11–13). American Association of Neurological Surgeons. [ISBN:1879284367]
External Links
Human Metabolome Database
HMDB01935
KEGG Compound
C01541
ChemSpider
10442445
BindingDB
50343352
ChEBI
87732
ChEMBL
CHEMBL1464
Therapeutic Targets Database
DAP000770
PharmGKB
PA451906
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Warfarin
ATC Codes
B01AA03 — Warfarin
AHFS Codes
  • 20:12.04.08 — Coumarin Derivatives
FDA label
Download (641 KB)
MSDS
Download (59.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherNeoplasms1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentOsteoarthritis of the Knees1
1CompletedNot AvailableHealthy Volunteers3
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamics of Warfarin / Pharmacokinetics of Isavuconazole / Pharmacokinetics of S- and R-warfarin1
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailableMalignant Lymphomas / Tumors, Solid1
1CompletedNot AvailableThrombosis, Venous1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceAnticoagulant Effect of Warfarin When Taken With Duloxetine1
1CompletedBasic ScienceAtopic Dermatitis (AD)1
1CompletedBasic ScienceDrug Drug Interactions / Healthy Volunteers1
1CompletedBasic ScienceDrug Interaction Potentiation1
1CompletedBasic ScienceHealthy Volunteers4
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of FG-45921
1CompletedBasic ScienceHealthy Volunteers / Rheumatoid Arthritis1
1CompletedBasic ScienceOveractive Bladder / Pharmacokinetics1
1CompletedBasic SciencePharmakokinetic1
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedOtherHealthy Volunteers2
1CompletedPreventionHealthy Volunteers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedScreeningHealthy Volunteers1
1CompletedTreatmentAlzheimer's Disease (AD) / Huntington's Disease (HD)1
1CompletedTreatmentCancers1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1CompletedTreatmentDiabetes / Healthy Volunteers1
1CompletedTreatmentDiabetes / Healthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentHaematological Malignancies / Tumors, Solid1
1CompletedTreatmentHealthy Volunteers14
1CompletedTreatmentHealthy Volunteers / Hemostasis1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentParkinson's Disease (PD)2
1CompletedTreatmentPsoriasis2
1CompletedTreatmentSystemic Embolism / Thrombophlebitis1
1CompletedTreatmentType 2 Diabetes Mellitus4
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentUrinary Bladder, Overactive1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1
1Not Yet RecruitingTreatmentCytochrome P450 Interaction1
1Not Yet RecruitingTreatmentDrug Interaction Potential1
1RecruitingBasic ScienceNeoplasms Metastasis1
1RecruitingOtherALK-positive Advanced Tumors1
1Unknown StatusTreatmentAnticoagulation1
1Unknown StatusTreatmentStrokes1
1WithdrawnBasic SciencePharmacodynamics / Pharmacokinetics1
1WithdrawnTreatmentHealthy Volunteers1
1WithdrawnTreatmentStroke, Ischemic1
1, 2RecruitingTreatmentVenous Thromboembolism1
2CompletedPreventionArthroplasty, Replacement, Knee1
2CompletedPreventionDeep Vein Thrombosis (DVT) / Nonvalvular Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
2CompletedPreventionNonvalvular Atrial Fibrillation8
2CompletedPreventionNonvalvular Atrial Fibrillation / Strokes1
2CompletedPreventionNonvalvular Atrial Fibrillation / Thromboembolism1
2CompletedPreventionPersistent or Permanent Nonvalvular Atrial Fibrillation1
2CompletedTreatmentDeep Vein Thrombosis (DVT) / Thrombosis, Venous1
2CompletedTreatmentEmbolism and Thrombosis1
2CompletedTreatmentFibrosis, Liver1
2CompletedTreatmentHeart Valve Diseases / Nonvalvular Atrial Fibrillation / Thrombosis, Venous1
2CompletedTreatmentMyocardial Infarction (MI) / Nonvalvular Atrial Fibrillation / Stroke, Ischemic / Venous Thromboembolism1
2CompletedTreatmentNonvalvular Atrial Fibrillation3
2CompletedTreatmentProstate Cancer / Thromboembolism1
2CompletedTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
2Not Yet RecruitingTreatmentCerebral Venous Thrombosis1
2RecruitingPreventionMyocardial Infarction (MI)1
2RecruitingTreatmentResidual Pulmonary Hypertension1
2RecruitingTreatmentThrombosis1
2RecruitingTreatmentValvular Heart Disease1
2TerminatedPreventionHeart Valve Diseases1
2TerminatedPreventionHeart Valve Prosthesis / Thromboembolism1
2TerminatedTreatmentHaemorrhage / Thrombosis1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2TerminatedTreatmentCardiac surgery, heparin-induced thrombocytopenia and thrombosis syndrome1
2WithdrawnNot AvailableNonvalvular Atrial Fibrillation1
2, 3CompletedPreventionNonvalvular Atrial Fibrillation / Strokes1
2, 3CompletedPreventionProphylaxis of Pulmonary embolism / Thrombosis, Venous1
2, 3RecruitingPreventionCoronary Artery Bypass Grafting (CABG) Surgery / Deep Venous Thrombosis / Postoperative Atrial Fibrilation / Strokes / Systemic Embolism1
2, 3TerminatedTreatmentPrimary Disease1
2, 3Unknown StatusTreatmentAtrial Flutter / Myocardial Infarction (MI) / Nonvalvular Atrial Fibrillation / Prophylaxis of cardiomyopathy / Venous Thromboembolic Diseases1
3CompletedNot AvailableCardiovascular Disease (CVD) / Thrombosis, Venous / Venous Thromboembolism1
3CompletedPreventionAnticoagulation in Pregnancy1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Cerebral Embolism and Thrombosis / Cerebrovascular Accidents / Cerebrovascular Disorders / Heart Diseases / Nonvalvular Atrial Fibrillation / Thrombophlebitis1
3CompletedPreventionAtrial Flutter / Nonvalvular Atrial Fibrillation1
3CompletedPreventionBrain Infarction / Systemic Embolism / Transient Ischaemic Attack (TIA)1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedPreventionCardiovascular Disease (CVD) / Heart Diseases / Peripheral Vascular Disease (PVD) / Thromboembolism / Vascular Diseases / Venous Thromboembolism1
3CompletedPreventionEnd Stage Renal Disease (ESRD) / Haemorrhage / Thrombosis1
3CompletedPreventionHeart Diseases / Ischaemic Heart Diseases / Myocardial Infarction (MI) / Strokes1
3CompletedPreventionNonvalvular Atrial Fibrillation1
3CompletedPreventionNonvalvular Atrial Fibrillation / Strokes1
3CompletedPreventionNonvalvular Atrial Fibrillation / Strokes / Systemic Embolism2
3CompletedPreventionThromboembolism1
3CompletedTreatmentArterial Occlusive Diseases / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Heart Diseases / Vascular Diseases1
3CompletedTreatmentCarotid Artery Dissection / Cervical Artery Dissection / Strokes / Vertebral Artery Dissection1
3CompletedTreatmentDeep Vein Thrombosis (DVT)1
3CompletedTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Thromboembolism / Thrombosis, Venous / Venous Thromboembolism1
3CompletedTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
3CompletedTreatmentIdiopathic Deep Vein Thrombosis / Recurrent Venous Thromboembolism1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentNonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentSystemic Embolism / Thrombosis1
3CompletedTreatmentThromboembolism3
3CompletedTreatmentThrombosis, Venous1
3CompletedTreatmentVenous Thromboembolism1
3CompletedTreatmentProphylaxis of Pulmonary embolism2
3Not Yet RecruitingPreventionRheumatic Heart Disease1
3Not Yet RecruitingPreventionThromboembolism / Thrombosis1
3Not Yet RecruitingTreatmentAcute Myocardial Infarction (AMI) / Anticoagulants and Bleeding Disorders / Left Ventricular Thrombosis1
3Not Yet RecruitingTreatmentCerebral Venous Thrombosis1
3Not Yet RecruitingTreatmentMV(Mitral Valve) Repair1
3Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
3Not Yet RecruitingTreatmentVenous Thromboembolism1
3RecruitingPreventionCardioembolic Stroke / Nonvalvular Atrial Fibrillation1
3RecruitingPreventionNonvalvular Atrial Fibrillation / Strokes / Transient Ischaemic Attack (TIA)1
3RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism / Venous Thromboembolism (VTE)1
3RecruitingTreatmentIndications for Warfarin Therapy1
3RecruitingTreatmentLeft Ventricular Thrombosis1
3RecruitingTreatmentLiver Cirrhosis / Oesophageal varices haemorrhage / Portal Vein Thrombosis / Portal Vein, Cavernous Transformation Of1
3RecruitingTreatmentNonvalvular Atrial Fibrillation1
3RecruitingTreatmentThromboembolism1
3RecruitingTreatmentCardiac surgery, heparin-induced thrombocytopenia and thrombosis syndrome1
3TerminatedPreventionAtherosclerosis / Cerebral Infarctions / Constriction, Pathologic / Strokes1
3TerminatedPreventionNonvalvular Atrial Fibrillation1
3TerminatedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism1
3Unknown StatusPreventionCardiovascular Disease (CVD) / Peripheral Vascular Disease (PVD)1
3Unknown StatusTreatmentNonvalvular Atrial Fibrillation / Strokes1
4Active Not RecruitingOtherDisorders, Blood Coagulation1
4Active Not RecruitingTreatmentDeep Venous Thrombosis / DVT / Nonvalvular Atrial Fibrillation / Thromboembolism / Thrombus Due to Heart Valve Prosthesis1
4Active Not RecruitingTreatmentNonvalvular Atrial Fibrillation2
4CompletedNot AvailableDrug Therapy, Combination1
4CompletedNot AvailableHealthy Volunteers1
4CompletedPreventionPatent Foramen Ovale (PFO) / Stroke, Ischemic1
4CompletedTreatmentAcute Gastrointestinal Bleeding1
4CompletedTreatmentBlood Clotting1
4CompletedTreatmentDeep Vein Thrombosis (DVT)2
4CompletedTreatmentDeep-Vein Thrombosis1
4CompletedTreatmentDisorders, Blood Coagulation1
4CompletedTreatmentHaemorrhage / Nonvalvular Atrial Fibrillation / Strokes / Thrombo-embolism1
4CompletedTreatmentHaemorrhage / Thromboembolism1
4CompletedTreatmentHemorrhage / Systemic Embolism / Thrombosis1
4CompletedTreatmentHypertensive / Liver Cirrhosis / Status;Splenectomy / Thrombosis, Venous1
4CompletedTreatmentNonvalvular Atrial Fibrillation3
4CompletedTreatmentOligohydramnios1
4Not Yet RecruitingSupportive CareProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4Not Yet RecruitingTreatmentLeft Atrial Appendage Closure / Non-valvular Atrial Fibrillation (NVAF)1
4Not Yet RecruitingTreatmentLiver Cirrhosis / Portal Vein Thrombosis1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation / Valve Heart Disease1
4RecruitingOtherCerebral Ischemic Events / Cognition Disorders / Dementias1
4RecruitingPreventionAntiphospholipid Syndrome / Recurrent Miscarriages1
4RecruitingPreventionAntiphospholipid Syndrome / Thrombosis1
4RecruitingPreventionAtherosclerosis1
4RecruitingPreventionHypertensive / Liver Cirrhosis / Status;Splenectomy / Thrombosis, Venous1
4RecruitingPreventionNonvalvular Atrial Fibrillation1
4RecruitingTreatmentAngiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy / Dabigatran Etexilate / Prophylaxis of Pulmonary embolism / Recurrence of DVT / Warfarin1
4RecruitingTreatmentAnticoagulating Treatment on a Duration at Least 12-month-old Superior / Anticoagulation Treatment at Least > or = to 12-month / Permanent Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Thrombosis, Venous1
4RecruitingTreatmentAnticoagulation / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentCoronary Artery Disease / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentDiabetes1
4RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentLiver Cirrhosis / Portal Vein Thrombosis1
4TerminatedNot AvailableCoronary Artery Bypass Graft Surgery / Presence of Heparin/Platelet Factor 4 Antibody1
4TerminatedTreatmentNonvalvular Atrial Fibrillation1
4TerminatedTreatmentProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4Unknown StatusNot AvailableHeart Valve Disease / Nonvalvular Atrial Fibrillation / Pulmonary Artery Embolism1
4Unknown StatusPreventionComplications Due to Heart Valve Prosthesis1
4WithdrawnPreventionChronic Kidney Disease (CKD) / Nonvalvular Atrial Fibrillation1
4WithdrawnTreatmentComplications; Arthroplasty1
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation / Thrombus Due to Heart Valve Prosthesis1
Not AvailableActive Not RecruitingNot AvailableStroke, Ischemic1
Not AvailableCompletedNot AvailableAtrial Fibrillation and Flutter1
Not AvailableCompletedNot AvailableHeart Valve Disease1
Not AvailableCompletedNot AvailableMajor Bleeding / Venous Thromboembolism1
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation5
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation / Strokes Thrombotic1
Not AvailableCompletedBasic ScienceDrug Interactions / Healthy Volunteers / Warfarin1
Not AvailableCompletedBasic ScienceHealthy Volunteers2
Not AvailableCompletedBasic SciencePharmacokinetics1
Not AvailableCompletedPreventionCardiac Pacing / Complications / Thrombosis, Venous1
Not AvailableCompletedSupportive CareThromboembolism1
Not AvailableCompletedTreatmentDeep Vein Thrombosis (DVT) / Nonvalvular Atrial Fibrillation / Prophylaxis of Pulmonary embolism1
Not AvailableCompletedTreatmentMetachromatic Leukodystrophy1
Not AvailableCompletedTreatmentMyocardial Infarction (MI)1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableEnrolling by InvitationTreatmentAnticoagulation1
Not AvailableEnrolling by InvitationTreatmentCardiovascular Disease (CVD) / Heart Failure, Unspecified1
Not AvailableNot Yet RecruitingNot AvailableNonvalvular Atrial Fibrillation2
Not AvailableNot Yet RecruitingNot AvailablePulmonary Arterial Hypertension (PAH)1
Not AvailableNot Yet RecruitingPreventionHemorrhage, Gastrointestinal / Post Polypectomy Bleeding in Anticoagulated Patients1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAnticoagulants and Bleeding Disorders / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableRecruitingNot AvailableProphylaxis of Pulmonary embolism1
Not AvailableRecruitingDiagnosticAortic Valve Disorder1
Not AvailableRecruitingOtherHealthy Volunteers1
Not AvailableRecruitingSupportive CareHemorrhage / Nonvalvular Atrial Fibrillation / Periodontal Diseases1
Not AvailableRecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / PTE - Pulmonary Thromboembolism1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
Not AvailableRecruitingTreatmentDeep Venous Thrombosis1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Portal Vein Thrombosis1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Thrombosis, Venous1
Not AvailableRecruitingTreatmentProsthetic Valve Thrombosis1
Not AvailableTerminatedNot AvailablePrescribers' Drug Orders1
Not AvailableTerminatedTreatmentVenous Thromboembolism1
Not AvailableUnknown StatusTreatmentDeep Venous Thromboembolism1
Not AvailableUnknown StatusTreatmentCardiac valve replacement / Deep Venous Thrombosis / Nonvalvular Atrial Fibrillation / Prophylaxis of Pulmonary embolism1
Not AvailableUnknown StatusTreatmentHeart; Complications, Valve, Prosthesis / Pregnancy1
Not AvailableUnknown StatusTreatmentIleofemoral Deep Vein Thrombosis1
Not AvailableUnknown StatusTreatmentThrombosis1
Not AvailableUnknown StatusTreatmentProphylaxis of Pulmonary embolism1
Not AvailableWithdrawnTreatmentAnticoagulation / Liver Cirrhosis / Portal Vein Thrombosis1

Pharmacoeconomics

Manufacturers
  • Pharmaceutical research assoc inc
  • Bristol myers squibb pharma co
  • Usl pharma inc
  • Abbott laboratories pharmaceutical products div
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Taro pharmaceuticals inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous2 mg/mL
Powder, for solutionIntravenous5 mg
TabletOral10 mg
TabletOral1 mg
TabletOral2.5 mg
TabletOral2 mg
TabletOral3 mg
TabletOral4 mg
TabletOral5 mg
TabletOral6 mg
TabletOral10.0 mg
TabletOral3.0 mg
TabletOral4.0 mg
TabletOral5.0 mg
TabletOral7.5 mg
TabletOral1 mg/1
TabletOral10 mg/1
TabletOral2 mg/1
TabletOral2.5 mg/1
TabletOral3 mg/1
TabletOral4 mg/1
TabletOral5 mg/1
TabletOral6 mg/1
TabletOral7.5 mg/1
Prices
Unit descriptionCostUnit
Warfarin sodium powder54.53USD g
Coumadin 5 mg vial34.07USD vial
Coumadin 10 mg tablet2.01USD tablet
Coumadin 7.5 mg tablet1.97USD tablet
Coumadin 6 mg tablet1.94USD tablet
Coumadin 3 mg tablet1.51USD tablet
Coumadin 5 mg tablet1.51USD tablet
Coumadin 4 mg tablet1.49USD tablet
Coumadin 2.5 mg tablet1.46USD tablet
Coumadin 2 mg tablet1.4USD tablet
Coumadin 1 mg tablet1.37USD tablet
Warfarin sodium 10 mg tablet1.0USD tablet
Warfarin sodium 7.5 mg tablet0.96USD tablet
Jantoven 10 mg tablet0.76USD tablet
Jantoven 7.5 mg tablet0.74USD tablet
Jantoven 6 mg tablet0.72USD tablet
Warfarin sodium 6 mg tablet0.68USD tablet
Warfarin sodium 3 mg tablet0.66USD tablet
Warfarin sodium 4 mg tablet0.66USD tablet
Warfarin sodium 2.5 mg tablet0.65USD tablet
Warfarin sodium 5 mg tablet0.65USD tablet
Warfarin sodium 2 mg tablet0.63USD tablet
Warfarin sodium 1 mg tablet0.61USD tablet
Jantoven 5 mg tablet0.59USD tablet
Jantoven 2 mg tablet0.56USD tablet
Jantoven 4 mg tablet0.56USD tablet
Jantoven 2.5 mg tablet0.53USD tablet
Jantoven 3 mg tablet0.53USD tablet
Coumadin 10 mg Tablet0.5USD tablet
Jantoven 1 mg tablet0.49USD tablet
Coumadin 3 mg Tablet0.43USD tablet
Coumadin 4 mg Tablet0.43USD tablet
Coumadin 2 mg Tablet0.35USD tablet
Coumadin 1 mg Tablet0.33USD tablet
Taro-Warfarin 7.5 mg Tablet0.33USD tablet
Taro-Warfarin 6 mg Tablet0.31USD tablet
Apo-Warfarin 10 mg Tablet0.28USD tablet
Coumadin 2.5 mg Tablet0.28USD tablet
Coumadin 5 mg Tablet0.28USD tablet
Mylan-Warfarin 10 mg Tablet0.28USD tablet
Taro-Warfarin 10 mg Tablet0.28USD tablet
Warfarin 10 mg Tablet0.28USD tablet
Apo-Warfarin 3 mg Tablet0.24USD tablet
Apo-Warfarin 4 mg Tablet0.24USD tablet
Mylan-Warfarin 3 mg Tablet0.24USD tablet
Mylan-Warfarin 4 mg Tablet0.24USD tablet
Novo-Warfarin 3 mg Tablet0.24USD tablet
Novo-Warfarin 4 mg Tablet0.24USD tablet
Taro-Warfarin 3 mg Tablet0.24USD tablet
Taro-Warfarin 4 mg Tablet0.24USD tablet
Warfarin 3 mg Tablet0.24USD tablet
Warfarin 4 mg Tablet0.24USD tablet
Apo-Warfarin 2 mg Tablet0.19USD tablet
Mylan-Warfarin 2 mg Tablet0.19USD tablet
Novo-Warfarin 2 mg Tablet0.19USD tablet
Taro-Warfarin 2 mg Tablet0.19USD tablet
Warfarin 2 mg Tablet0.19USD tablet
Apo-Warfarin 1 mg Tablet0.18USD tablet
Mylan-Warfarin 1 mg Tablet0.18USD tablet
Novo-Warfarin 1 mg Tablet0.18USD tablet
Taro-Warfarin 1 mg Tablet0.18USD tablet
Warfarin 1 mg Tablet0.18USD tablet
Apo-Warfarin 5 mg Tablet0.16USD tablet
Mylan-Warfarin 5 mg Tablet0.16USD tablet
Novo-Warfarin 5 mg Tablet0.16USD tablet
Taro-Warfarin 5 mg Tablet0.16USD tablet
Warfarin 5 mg Tablet0.16USD tablet
Apo-Warfarin 2.5 mg Tablet0.15USD tablet
Mylan-Warfarin 2.5 mg Tablet0.15USD tablet
Novo-Warfarin 2.5 mg Tablet0.15USD tablet
Taro-Warfarin 2.5 mg Tablet0.15USD tablet
Warfarin 2.5 mg Tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)161 °CPhysProp
water solubility17 mg/L (at 20 °C)TOMLIN,C (1997)
logP2.70HANSCH,C ET AL. (1995)
logS-3.89ADME Research, USCD
Caco2 permeability-4.68ADME Research, USCD
pKa5.08Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0472 mg/mLALOGPS
logP2.41ALOGPS
logP2.74ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)6.33ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity86.86 m3·mol-1ChemAxon
Polarizability31.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9109
Blood Brain Barrier+0.9124
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5502
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8863
CYP450 2C9 substrateNon-substrate0.678
CYP450 2D6 substrateSubstrate0.5658
CYP450 3A4 substrateNon-substrate0.6007
CYP450 1A2 substrateNon-inhibitor0.714
CYP450 2C9 inhibitorInhibitor0.7657
CYP450 2D6 inhibitorNon-inhibitor0.9286
CYP450 2C19 inhibitorNon-inhibitor0.9161
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8785
Ames testNon AMES toxic0.6844
CarcinogenicityNon-carcinogens0.9352
BiodegradationNot ready biodegradable0.7474
Rat acute toxicity4.1700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8768
hERG inhibition (predictor II)Non-inhibitor0.9615
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.72 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-014i-0293000000-848341bcbd6a3f0a2c6b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0429000000-1e818b579dc7a0fade2d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-f568338c06cd9b4762ac
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-acdd0ed19e403aa73c77
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0bt9-0539000000-5b1c7c6c812ba72325e3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0009000000-e461e1aca7977a2838ad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0w29-0960000000-9fa099190280529cd891
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0910000000-d7dbaf6e7b34ee85e1f7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0920000000-4fb886a5c160afa86df9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0920000000-ad608fe7680a2adf9d90
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ik9-0942000000-5864f2d15892753d6a8b

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Hydroxycoumarins
Direct Parent
4-hydroxycoumarins
Alternative Parents
1-benzopyrans / Pyranones and derivatives / Benzene and substituted derivatives / Vinylogous acids / Heteroaromatic compounds / Lactones / Ketones / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives
Substituents
4-hydroxycoumarin / Benzopyran / 1-benzopyran / Pyranone / Monocyclic benzene moiety / Benzenoid / Pyran / Heteroaromatic compound / Vinylogous acid / Ketone
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
methyl ketone, hydroxycoumarin (CHEBI:87732) / Coumarin rodenticides (C01541)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vitamin-k-epoxide reductase (warfarin-sensitive) activity
Specific Function
Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the...
Gene Name
VKORC1
Uniprot ID
Q9BQB6
Uniprot Name
Vitamin K epoxide reductase complex subunit 1
Molecular Weight
18234.3 Da
References
  1. Gebauer M: Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem. 2007 Mar 15;15(6):2414-20. Epub 2007 Jan 17. [PubMed:17275317]
  2. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007 Jul;53(7):1199-205. Epub 2007 May 17. [PubMed:17510308]
  3. Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11. [PubMed:17161452]
  4. Osman A, Enstrom C, Lindahl TL: Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype. Blood Coagul Fibrinolysis. 2007 Apr;18(3):293-6. [PubMed:17413769]
  5. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb;83(2):312-21. Epub 2007 Jul 25. [PubMed:17653141]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Rulcova A, Prokopova I, Krausova L, Bitman M, Vrzal R, Dvorak Z, Blahos J, Pavek P: Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost. 2010 Dec;8(12):2708-17. doi: 10.1111/j.1538-7836.2010.04036.x. [PubMed:20735727]

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Details
1. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M: Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochim Biophys Acta. 1996 Jul 18;1295(2):147-57. [PubMed:8695640]
  2. Joseph KS, Hage DS: The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan. J Pharm Biomed Anal. 2010 Nov 2;53(3):811-8. doi: 10.1016/j.jpba.2010.04.035. Epub 2010 May 6. [PubMed:20537832]
  3. Wybranowski T, Cyrankiewicz M, Ziomkowska B, Kruszewski S: The HSA affinity of warfarin and flurbiprofen determined by fluorescence anisotropy measurements of camptothecin. Biosystems. 2008 Dec;94(3):258-62. doi: 10.1016/j.biosystems.2008.05.034. Epub 2008 Jul 31. [PubMed:18721856]
  4. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]
Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Hazai E, Visy J, Fitos I, Bikadi Z, Simonyi M: Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. Bioorg Med Chem. 2006 Mar 15;14(6):1959-65. Epub 2005 Nov 15. [PubMed:16290938]
  2. Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K: Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol. 2003 Dec;56(6):664-9. [PubMed:14616427]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13